Description

Kadcyla 160 mg contains Trastuzumab Emtansine (T-DM1), an antibody-drug conjugate (ADC) designed to target HER2-positive cancer cells. It combines the HER2-targeting monoclonal antibody trastuzumab with the chemotherapy agent DM1 (emtansine), allowing precise delivery of chemotherapy to cancer cells.

🔬 Mechanism of Action

Trastuzumab Emtansine binds to the HER2 receptor on cancer cells. After binding:

• The complex is internalized into the tumor cell
• The cytotoxic agent DM1 is released inside the cell
• DM1 disrupts microtubule function, leading to cancer cell death

This targeted approach helps minimize damage to healthy cells compared to conventional chemotherapy.

💊 Indications of Kadcyla 160 mg

Kadcyla 160 mg is indicated for:

• HER2-positive metastatic breast cancer in patients previously treated with trastuzumab and a taxane
• Adjuvant treatment of HER2-positive early breast cancer with residual disease after neoadjuvant therapy

📌 Key Features of Kadcyla 160 mg

• Strength: 160 mg
• Dosage Form: Intravenous infusion
• Therapeutic Class: Antibody-Drug Conjugate (ADC)
• Target: HER2-positive cancer cells
• Administration: IV infusion in hospital or oncology clinic
• Monitoring: Liver function tests, platelet counts, and cardiac monitoring recommended

⚕️ Benefits of Trastuzumab Emtansine

• Targeted delivery of chemotherapy
• Improved progression-free survival in HER2-positive breast cancer
• Reduced systemic toxicity compared to traditional chemotherapy
• Effective option after prior HER2-targeted therapy

⚠️ Precautions

• Risk of hepatotoxicity and thrombocytopenia
• Possible cardiotoxicity; cardiac monitoring required
• Infusion-related reactions may occur
• Not recommended during pregnancy
• Use strictly under oncologist supervision

Kadcyla 160 mg (Trastuzumab Emtansine Injection) represents an advanced targeted therapy for HER2-positive breast cancer, combining the precision of monoclonal antibodies with the effectiveness of chemotherapy to improve treatment outcomes.